UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 661

Sortiert nach

Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs

The Lancet (British edition), 2013-06, Vol.381 (9883), p.2109-2117

2013

Link zum Volltext

Verfügbarkeit prüfen

Antiretroviral exposure and comorbidities in an aging HIV-infected population: The challenge of geriatric patients

PloS one, 2018-09, Vol.13 (9), p.e0203895-e0203895

2018

Link zum Volltext

Verfügbarkeit prüfen

Classic and extracavitary primary effusion lymphoma in 51 HIV‐infected patients from a single institution

American journal of hematology, 2016-02, Vol.91 (2), p.233-237

2016

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial

The Lancet (British edition), 2007-04, Vol.369 (9569), p.1261-1269

2007

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials

AIDS (London), 2009-11, Vol.23 (17), p.2289-2300

2009

Link zum Volltext

Verfügbarkeit prüfen

Birth Country Influences the Choice of Antiretroviral Therapy in HIV-Infected Individuals: Experience From a French HIV Centre

Journal of acquired immune deficiency syndromes (1999), 2023-02, Vol.92 (2), p.144

2023

Link zum Volltext

Verfügbarkeit prüfen

Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection in HIV-Infected Patients

The New England journal of medicine, 2004-07, Vol.351 (5), p.438-450

2004

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial

The Lancet (British edition), 2007-07, Vol.370 (9581), p.39-48

2007

Link zum Volltext

Verfügbarkeit prüfen

Mutations Associated with Failure of Raltegravir Treatment Affect Integrase Sensitivity to the Inhibitor In Vitro

Antimicrobial Agents and Chemotherapy, 2008-04, Vol.52 (4), p.1351-1358

2008

Link zum Volltext

Verfügbarkeit prüfen

The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults : the first 4 years

AIDS (London), 2007-06, Vol.21 (10), p.1273-1281

2007

Link zum Volltext

Verfügbarkeit prüfen

A need for implementation science to optimise the use of evidence-based interventions in HIV care: A systematic literature review

PloS one, 2019-08, Vol.14 (8), p.e0220060-e0220060

2019

Link zum Volltext

Verfügbarkeit prüfen

Household transmission of SARS-CoV-2 infection in the Paris/Ile-de-France area

European journal of clinical microbiology & infectious diseases, 2022-03, Vol.41 (3), p.445-454

2022

Link zum Volltext

Verfügbarkeit prüfen

Body composition and adipokines changes after initial treatment with darunavir-ritonavir plus either raltegravir or tenofovir disoproxil fumarate-emtricitabine: A substudy of the NEAT001/ANRS143 randomised trial

PloS one, 2019-01, Vol.14 (1), p.e0209911-e0209911

2019

Link zum Volltext

Verfügbarkeit prüfen

Preferential amplification of CD8 effector-T cells after transcutaneous application of an inactivated influenza vaccine: a randomized phase I trial

PloS one, 2010-05, Vol.5 (5), p.e10818

2010

Link zum Volltext

Verfügbarkeit prüfen

AIDS-Related Malignancies: State of the Art and Therapeutic Challenges

Journal of clinical oncology, 2008-10, Vol.26 (29), p.4834-4842

2008

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients : 24-week results of POWER 1

AIDS (London), 2007-02, Vol.21 (4), p.395-402

2007

Link zum Volltext

Verfügbarkeit prüfen

Risk Factors of Chronic Kidney Disease in HIV-infected Patients

Clinical journal of the American Society of Nephrology, 2011-07, Vol.6 (7), p.1700-1707

2011

Link zum Volltext

Verfügbarkeit prüfen

HIV

The Lancet (British edition), 2018-08, Vol.392 (10148), p.685-697

2018

Link zum Volltext

Verfügbarkeit prüfen

Virological efficacy of switch to DTG plus 3TC in a retrospective observational cohort of suppressed HIV-1 patients with or without past M184V – The LAMRES Study

Journal of global antimicrobial resistance., 2022-12, Vol.31, p.52-62

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 661

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(607)
Mit Volltextzugriff
(578)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(502)
Life Sciences & Biomedicine
(479)
Humans
(473)
Infectious Diseases
(415)
Male
(308)
Hiv Infections - Drug Therapy
(301)
Adult
(275)
Female
(262)
Biological And Medical Sciences
(257)
Medical Sciences
(255)
Middle Aged
(234)
Immunology
(223)
Hiv
(222)
Virology
(212)
Human Immunodeficiency Virus
(198)
Viral Diseases
(189)
Human Viral Diseases
(187)
Aids/hiv
(177)
Viral Diseases Of The Lymphoid Tissue And The Blood. Aids
(170)
Microbiology
(168)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs

Antiretroviral exposure and comorbidities in an aging HIV-infected population: The challenge of geriatric patients

Classic and extracavitary primary effusion lymphoma in 51 HIV‐infected patients from a single institution

Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial

Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials

Bone mineral density and inflammatory and bone biomarkers after darunavir–ritonavir combined with either raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial

Birth Country Influences the Choice of Antiretroviral Therapy in HIV-Infected Individuals: Experience From a French HIV Centre

Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection in HIV-Infected Patients

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial

Mutations Associated with Failure of Raltegravir Treatment Affect Integrase Sensitivity to the Inhibitor In Vitro

The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults : the first 4 years

A need for implementation science to optimise the use of evidence-based interventions in HIV care: A systematic literature review

Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial

Household transmission of SARS-CoV-2 infection in the Paris/Ile-de-France area

Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trial

Body composition and adipokines changes after initial treatment with darunavir-ritonavir plus either raltegravir or tenofovir disoproxil fumarate-emtricitabine: A substudy of the NEAT001/ANRS143 randomised trial

Preferential amplification of CD8 effector-T cells after transcutaneous application of an inactivated influenza vaccine: a randomized phase I trial

AIDS-Related Malignancies: State of the Art and Therapeutic Challenges

Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients : 24-week results of POWER 1

A single HIV-1 cluster and a skewed immune homeostasis drive the early spread of HIV among resting CD4+ cell subsets within one month post-infection

Risk Factors of Chronic Kidney Disease in HIV-infected Patients

HIV

Virological efficacy of switch to DTG plus 3TC in a retrospective observational cohort of suppressed HIV-1 patients with or without past M184V – The LAMRES Study

Suchergebnisse filtern